Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
Myeloid folliculin balances mTOR activation to maintain innate immunity homeostasis
Jia Li, Shogo Wada, Lehn K. Weaver, Chhanda Biswas, Edward M. Behrens, Zoltan Arany
Jia Li, Shogo Wada, Lehn K. Weaver, Chhanda Biswas, Edward M. Behrens, Zoltan Arany
View: Text | PDF
Research Article Cell biology Immunology

Myeloid folliculin balances mTOR activation to maintain innate immunity homeostasis

  • Text
  • PDF
Abstract

The mTOR pathway is central to most cells. How mTOR is activated in macrophages and how it modulates macrophage physiology remain poorly understood. The tumor suppressor folliculin (FLCN) is a GAP for RagC/D, a regulator of mTOR. We show here that LPS potently suppresses FLCN in macrophages, allowing nuclear translocation of the transcription factor TFE3, leading to lysosome biogenesis, cytokine production, and hypersensitivity to inflammatory signals. Nuclear TFE3 additionally activates a transcriptional RagD-positive feedback loop that stimulates FLCN-independent canonical mTOR signaling to S6K and increases cellular proliferation. LPS thus simultaneously suppresses the TFE3 arm and activates the S6K arm of mTOR. In vivo, mice lacking myeloid FLCN reveal chronic macrophage activation, leading to profound histiocytic infiltration and tissue disruption, with hallmarks of human histiocytic syndromes, such as Erdheim-Chester disease. Our data thus identify a critical FLCN-mTOR-TFE3 axis in myeloid cells, modulated by LPS, that balances mTOR activation and curbs innate immune responses.

Authors

Jia Li, Shogo Wada, Lehn K. Weaver, Chhanda Biswas, Edward M. Behrens, Zoltan Arany

×

Figure 2

LPS but not CpG suppresses FLCN expression and subsequently induces TFE3 nuclear translocation.

Options: View larger image (or click on image) Download as PowerPoint
LPS but not CpG suppresses FLCN expression and subsequently induces TFE3...
(A) FLCN expression was determined in BMDMs exposed to CpG (10 μg/ml) or LPS (100 ng/ml) stimulation for 0, 6, 12, and 24 hours. (B) Immunofluorescence staining of TFE3 (green) in BMDMs exposed to vehicle, CpG, or LPS stimulation up to 24 hours. Scale bar: 10 μm. The bar graph shows quantification of TFE3 nuclear translocation from C. Values are represented as mean ± SEM. *P < 0.05, **P < 0.01 vs. vehicle, by 1-way ANOVA followed by t test (Bonferroni correction) (n = 10, >160 cells per trial). (C) Nuclear-cytoplasmic fractionation of phospho-TFE3 (Ser320) and TFE3 expression in BMDMs exposed to CpG or LPS stimulation for 0, 6, 12, and 24 hours. Treatment with the mTOR inhibitor Torin-1 (250 nM) for 3 hour served as a positive control. Histone H3 serves as a specific marker of nuclear fraction. (D) Immunofluorescence staining of FLCN-HA (red) and TFE3 (green) in LPS-stimulated BMDMs. Overexpression of doxycycline-inducible FLCN-HA blocked the redistribution of TFE3 from the cytosol to nucleus induced by LPS. DOX, doxycycline (1 μg/ml, 24 hours). Scale bar: 10 μm.

Copyright © 2026 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts